Literature DB >> 24361997

Perioperative complications related to minimally invasive transforaminal lumbar fusion: evaluation of 204 operations on lumbar instability at single center.

Jian Wang1, Yue Zhou2.   

Abstract

BACKGROUND CONTEXT: Minimally invasive transforaminal lumbar fusion (MIS-TLIF) has demonstrated efficacy in the treatment of lumbar degenerative diseases. The reported incidence of perioperative complications associated with MIS-TLIF surgery is highly variable. Studies concerning perioperative complications in broad patient populations are quite rare. This study analyzes a retrospectively collected database of patients who underwent an MIS-TLIF surgery at a single center.
PURPOSE: To determine the incidence of perioperaive complications with MIS-TLIF procedure based on our definition of Type I and II perioperative complications. STUDY
DESIGN: Retrospective cohort study; a review of complications. PATIENT SAMPLE: The sample comprises 204 patients who underwent MIS-TLIF for the treatment of lumbar degenerative diseases. OUTCOME MEASURES: Type I complication including all medical adverse events without direct connection to the specific surgical procedure performed. Type II complication including adverse events with direct connection to the surgical procedure performed.
METHODS: A total of 204 MIS-TLIF surgeries on lumbar instability or spondylolisthesis, performed between June 2007 and July 2012, were examined in a retrospective study. A complication classification based on the relation to the surgical procedure and the effect duration was used. Perioperative complications until 1 month postoperatively were reviewed for the patients.
RESULTS: The study group comprised 204 patients (106 women, 98 men; mean age at surgery, 52.4 years; age range, 39-84 years). Overall, there were 75 perioperative complications in 204 patients (36.76%). Only one complication occurred in 54 patients. Nine patients had two complications. One patient had three complications. The incidence of perioperative complication was 31.37% (64/204 patients) in the MIS-TLIF operations. Of all complications, seven (9.33%) were classified as persistent complications and 68 (90.67%) were classified as transient complications. The incidence of Type I and II complications were 13.73% and 23.04%, respectively.
CONCLUSIONS: Minimally invasive transforaminal lumbar fusion has gained popularity as a procedure for the treatment of lumbar instability or spondylolisthesis, with similar complications as in the open surgery. Transient sensory disturbance was the most common complication in this series.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complications; Degenerative lumbar diseases; Minimally invasive surgery; Minimally invasive transforaminal lumbar interbody fusion; Spine surgery; Spondylolisthesis

Mesh:

Year:  2013        PMID: 24361997     DOI: 10.1016/j.spinee.2013.12.016

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  16 in total

1.  Clinical and radiological outcomes of unilateral versus bilateral instrumentation in two-level degenerative lumbar diseases.

Authors:  Guangfei Gu; Hailong Zhang; Guoxin Fan; Shisheng He; Xiaotong Meng; Xin Gu; Ning Yan; Xiaofei Guan
Journal:  Eur Spine J       Date:  2015-05-23       Impact factor: 3.134

Review 2.  Minimally invasive transforaminal lumbar interbody fusion (MI-TLIF): A review of indications, technique, results and complications.

Authors:  Bhavuk Garg; Nishank Mehta
Journal:  J Clin Orthop Trauma       Date:  2019-01-14

Review 3.  Clinical outcomes after minimally invasive transforaminal lumbar interbody fusion and lateral lumbar interbody fusion for treatment of degenerative lumbar disease: a systematic review and meta-analysis.

Authors:  Gun Keorochana; Kitipong Setrkraising; Patarawan Woratanarat; Alisara Arirachakaran; Jatupon Kongtharvonskul
Journal:  Neurosurg Rev       Date:  2016-12-24       Impact factor: 3.042

4.  Postoperative dysesthesia in minimally invasive transforaminal lumbar interbody fusion: a report of five cases.

Authors:  Honggang Wang; Yue Zhou; Zhengfeng Zhang
Journal:  Eur Spine J       Date:  2016-02-05       Impact factor: 3.134

5.  [Clinical evaluation of minimally invasive transforaminal lumbar interbody fusion for severe lumbar spinal stenosis].

Authors:  Chao Yuan; Chao Liu; Junhong Shen; Huake Tian; Wenjie Zheng; Chao Zhang; Yong Pan; Bo Huang; Tao Jiang; Zhengfeng Zhang; Changqing Li; Jian Wang; Yue Zhou
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-07-15

6.  Risk Factors for Medical and Surgical Complications After Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion.

Authors:  Ankur S Narain; James M Parrish; Nathaniel W Jenkins; Brittany E Haws; Benjamin Khechen; Kelly H Yom; Krishna T Kudaravalli; Jordan A Guntin; Kern Singh
Journal:  Int J Spine Surg       Date:  2020-04-30

Review 7.  Lower complication and reoperation rates for laminectomy rather than MI TLIF/other fusions for degenerative lumbar disease/spondylolisthesis: A review.

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2018-03-07

8.  Influence of perioperative complication severity on 1- and 2-year outcomes of low back surgery.

Authors:  James Grainger; Thomas Hammett; Robert Isaacs; Chad Cook
Journal:  J Orthop Traumatol       Date:  2016-11-22

9.  Computer-assisted, minimally invasive transforaminal lumbar interbody fusion: One surgeon's learning curve A STROBE-compliant article.

Authors:  Yun-Feng Xu; Xiao-Feng Le; Wei Tian; Bo Liu; Qin Li; Gui-Lin Zhang; Ya-Jun Liu; Qiang Yuan; Da He; Jian-Ping Mao; Bin Xiao; Zhao Lang; Xiao-Guang Han; Pei-Hao Jin
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

10.  Comparative effectiveness of two different interbody fusion methods for transforaminal lumbar interbody fusion: cage versus morselized impacted bone grafts.

Authors:  Chaoliang Lv; Xianzhou Li; Haicheng Zhang; Junrong Lv; Hongmei Zhang
Journal:  BMC Musculoskelet Disord       Date:  2015-08-19       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.